Upstream Bio, Inc. operates as a clinical-stage biotechnology company. The Company focuses on developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. Upstream Bio serves customers in the United States.

Current Report (Form 8-K | Period ending 2024-10-10)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Upstream Bio (UPB US)

Current Report (Form 8-K | Period ending 2024-10-10)

S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

424B4 | Prospectus

S-1MEF | A new registration statement filed under Rule 462(b) to add securities to a prior related effective registration statement filed on Form S 1

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)